VIVEbiotech has participated in the 26th Congress of the European Society of Gene and Cell Therapy (ESGCT) that took place in Lausanne, Switzerland, on 16, 17, 18 and 19 October. It was a collaborative conference between the ESGCT, the ISSCR (International Society for Stem Cell Research) and the SFTCG (Société Française de Thérapie Cellulaire et Génique).

VIVEbiotech has signed three new contracts for the production of lentiviral vectors for three clinical trials for an amount of 1.4 million euros. Two of them are to supply lentiviruses to two European hospitals (one Spanish and one Swiss), and the third one to a Norwegian company.

Biospain is a biennial biotechnology event organized by Asebio (Spanish Association of Biocompanies) in which more than 3000 individual meetings are held and more than 800 companies participate. The last edition took place at the end of September in Seville.

VIVEbiotech S.L. has obtained the CIR certification (Crédit d'Impôt Recherche) which reinforces its position as an R & D provider for the French market.

VIVEbiotech will participate in the International Conference on Lymphocyte Engineering that will take place in Madrid from the 13th to the 15th of September.

The Commission of Economic Promotion of the General Councils of Gipuzkoa visited the facilities of VIVEbiotech. Throughout the visit, the Commission was able to learn about the production process and development of the lentiviral vectors that VIVEbiotech manufactures contributing to the treatment of diseases of genetic origin such as many of the rare diseases, as well as cancer.